iShares Nasdaq Biotechnology ETF (IBB) has been moving in the right direction lately, mostly because the risk of an aggressive healthcare reform that could dramatically affect pricing power for biotech stocks has significantly declined in recent months.
Moving forward, the ETF still has a lot of room to recover in the years ahead, the fundamentals look strong at the portfolio level, and relative strength is a major return driver for iShares Nasdaq Biotechnology ETF.
A Major Catalyst For Biotech
Investors have been heavily concerned about the impact of regulatory risk on the healthcare